M
Myrobalan Therapeutics
Harnessing common disease mechanisms to create breakthrough small molecule therapeutics
About Myrobalan Therapeutics
Myrobalan Therapeutics is a biotechnology firm established in 2021, focusing on the development of oral neurorestorative therapies aimed at reversing key pathological processes in central nervous system (CNS) disorders. The company was co-founded by an experienced team including Dr. Alex Nivorozhkin, who serves as the President and Chief Executive Officer, Dr. Steven Gullans, the Chief Scientific Officer, and Dr. Jin-A Lee, the Director of R&D. The founders bring a wealth of experience in drug discovery and development, particularly in the CNS space, having previously worked together at pioneering companies like Gensaic, which also focused on CNS therapeutics. Dr. Nivorozhkin has a notable track record in identifying and advancing novel therapeutic candidates from inception to clinical trials.
The company's core mission is to address significant unmet needs in neurodegenerative, demyelinating, and neuropsychiatric disorders by promoting remyelination, the process of rebuilding the protective myelin sheath around nerves. Its primary therapeutic candidate, MRO-103, is an orally administered small molecule designed to stimulate the generation of new oligodendrocytes, the cells responsible for myelination in the brain. This approach holds potential for treating conditions like multiple sclerosis, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS) by not just slowing disease progression but potentially restoring neurological function. Myrobalan operates on a research and development-centric business model, likely generating future revenue through partnerships, licensing agreements with larger pharmaceutical companies, or the eventual commercialization of its therapeutic candidates following successful clinical trials and regulatory approval.
In a significant milestone, Myrobalan Therapeutics secured a $24 million Series A financing round in 2021, co-led by founding investor OrbiMed and Samsara BioCapital. This funding is being utilized to advance its pipeline of remyelinating therapies, with the goal of bringing its lead candidate, MRO-103, into clinical development. The company's strategy involves a deep understanding of the underlying biology of CNS disorders to develop targeted and effective treatments that can offer substantial improvements over existing therapies.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jul 2024 | $9M | $120M | Undisclosed | ↗ |
| GRANT✓Other financing | Feb 2024 | $400K | — | The ALS Association | ↗ |
Growth signals
Latest recorded traffic for Myrobalan Therapeutics is 6.1K monthly website visits, up 306.7% over the last three months. Myrobalan Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Myrobalan Therapeutics in the Medford ecosystem
The Myrobalan Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
The ALS Association
Series A4 investors entered at this stage
3E Bioventures
AB Magnitude Ventures- GIGuan Zi Equity Investment
Cowin Venture
Other known investors1 additional known investor
Harvard University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Myrobalan Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Myrobalan Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








